Skip to main content

Quadriga BioSciences Doses First Patient in Phase I Clinical Trial of LAT1-Targeting Agent

NEW YORK – Los Altos, California-based Quadriga BioSciences on Thursday announced that the first patient had been dosed in its Phase I, dose-escalation study of QBS10072S, a bifunctional amino acid analogue for the treatment of patients with metastatic cancer.

The first-in-class agent was developed to target cancer cells that express the L-type amino acid transporter 1 (LAT1), while sparing the cells of neighboring normal tissue, which do not typically express LAT1. The agent has demonstrated in preclinical studies that it is able to successfully cross the blood-brain barrier to target brain cancers and brain metastases.

For the Phase I study, Quadriga — in collaboration with NBQ, the company's China-based joint venture — plans to enroll roughly 50 patients with previously treated cancers demonstrating high LAT1 signatures as well as patients with relapsed or refractory grade 4 astrocytoma, also known as glioblastoma multiforme. The primary aims of the study are to determine the maximum tolerated dose, pharmacokinetics, and preliminary anti-tumor activity of QBS10072S.

While the study will enroll patients with a wide range of malignancies, including breast, brain, and lung cancer, among over a dozen other tumor types, the study design will also allow the investigators to assess the agent in separate disease-specific expansion cohorts comprising patients with brain metastases and astrocytoma, respectively.

"We believe this program has the potential to significantly help patients with brain metastases and those with late-stage astrocytoma," Quadriga CEO Gordon Ringold said in a statement.